Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On January 12, 2011, administrators notified the company of an increase in interests in Ordinary share ADRs for specific individuals following the re-investment of dividends paid on January 6, 2011. The transaction price was $39.05 per ADR.
- Mr E J Gray: Increase of 17.31 ADRs.
- Mr D J Phelan: Increase of 524.83 ADRs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding insider trading rules (Disclosure and Transparency Rule 3.1.4R(1)(a)).
Investor Verification Points
- Verify the total number of ADRs held by Mr E J Gray and Mr D J Phelan post-transaction.
- Confirm the dividend reinvestment terms for the SmithKline Beecham Mid-Term Incentive Plan.
- Check the market price of GSK ADRs on January 6, 2011, to validate the $39.05 transaction price.